Arrowhead Pharmaceuticals, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 138.29M | 243.23M | 240.74M | 3.55M | 829.45M | 23258.2% | |
| Cost of Revenue | — | (10.42M) | (12.49M) | (18.59M) | — | -100.0% | |
Gross Profit | 138.29M | 232.81M | 228.24M | -15.04M | 829.45M | -5613.5% | |
| Operating Expenses | |||||||
| Research & Development | (198.98M) | (288.50M) | (342.31M) | (489.22M) | (607.16M) | 24.1% | |
| Selling, General & Administrative | (80.98M) | (124.43M) | (90.93M) | (96.82M) | (121.92M) | 25.9% | |
| General & Administrative | (80.98M) | (124.43M) | (90.93M) | (96.82M) | (121.92M) | 25.9% | |
| Depreciation & Amortization | (8.27M) | (10.42M) | (12.49M) | (18.59M) | (23.93M) | 28.7% | |
Operating Income (EBIT) | -149.04M | -178.51M | -205.00M | -601.08M | 98.35M | -116.4% | |
| Non-Operating Items | |||||||
| Interest Income | 6.12M | 5.03M | 15.30M | 22.72M | 37.29M | 64.1% | |
| Interest Expense | — | — | (18.33M) | (32.35M) | (89.36M) | 176.2% | |
| Other Income/Expenses (Net) | 8.19M | 5.80M | -1.49M | -11.38M | -46.81M | 311.4% | |
Income Before Tax | -140.85M | -172.71M | -206.49M | -612.46M | 51.53M | -108.4% | |
| Income Tax Expense | (2.00K) | (3.79M) | (2.78M) | (2.77M) | (21.42M) | -874.1% | |
Net Income | -140.85M | -176.06M | -205.28M | -599.49M | -1.63M | -99.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-1 | $-2 | $-2 | $-5 | $-0 | -99.8% | |
| Weighted Avg Shares Outstanding | 103.75M | 105.43M | 107.31M | 119.78M | 133.76M | 11.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 103.75M | 105.43M | 106.75M | 119.78M | 133.76M | 11.7% | |
EBITDA | -132.58M | -162.29M | -175.67M | -561.51M | 164.82M | -129.4% |
Explore ARWR
ARWR in the Healthcare
Large Cap